AMCINONIDE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for AMCINONIDE (AMCINONIDE).
Corticosteroid that binds to glucocorticoid receptors, modulating gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress inflammatory cell migration and cytokine production.
| Metabolism | Primarily hepatic metabolism via CYP3A4; metabolites are excreted renally. |
| Excretion | Primarily renal; <5% fecal. About 40% of a dose is excreted in urine as unchanged drug and glucuronide conjugates. |
| Half-life | Terminal elimination half-life is approximately 2–4 hours, but following topical application, systemic half-life may be prolonged due to continuous absorption from the skin. |
| Protein binding | Approximately 95–99% bound to plasma proteins, primarily albumin and corticosteroid-binding globulin. |
| Volume of Distribution | Apparent volume of distribution is about 0.14–0.3 L/kg, indicating extensive tissue distribution. |
| Bioavailability | Topical: Bioavailability is high but variable due to skin barrier; systemic absorption ranges from 0.5% to 2% with intact skin, higher with occlusion or inflamed skin. Intralesional: Complete systemic absorption. |
| Onset of Action | Topical: Onset of anti-inflammatory effect occurs within 2–4 hours after application. |
| Duration of Action | Topical: Duration of action is approximately 8–12 hours, with twice-daily application recommended for sustained effect. |
Topical: Apply a thin film to affected skin areas twice daily. Maximum 60 g per week. Use for no longer than 2 consecutive weeks.
| Dosage form | LOTION |
| Renal impairment | No adjustment required for topical use. Systemic absorption is minimal. |
| Liver impairment | No adjustment required for topical use. Systemic absorption is minimal. |
| Pediatric use | Use lowest effective dose for shortest duration. Apply sparingly to small areas. Avoid use in children <2 years of age. For children ≥2 years: apply thin film once or twice daily. Limit treatment to 5-7 days. |
| Geriatric use | Use lowest effective dose for shortest duration. Apply sparingly due to thinner skin and increased systemic absorption risk. Avoid use on large areas or under occlusive dressings. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for AMCINONIDE (AMCINONIDE).
| Breastfeeding | No data available on excretion into breast milk. Systemic absorption after topical application is minimal but may occur with prolonged or large-area use. Caution should be exercised as a risk to the infant cannot be excluded. Use only if clearly needed and apply to smallest area for shortest duration. M/P ratio: Not established. |
| Teratogenic Risk | Pregnancy Category C. Topical corticosteroids, including amcinonide, have not been adequately studied in pregnant women. Animal studies have shown teratogenic effects with systemic administration, but the risk with topical application is low due to minimal systemic absorption. However, prolonged or large-area use may increase systemic absorption and potential fetal risk. First trimester: Avoid unless clearly needed. Second and third trimesters: Use with caution, avoiding extensive areas, prolonged use, or occlusive dressings. |
■ FDA Black Box Warning
None.
| Serious Effects |
["Hypersensitivity to amcinonide or any component of the formulation.","Untreated bacterial, viral, or fungal infections at the application site.","Topical application for ophthalmic or intravaginal use."]
| Precautions | ["Systemic absorption with prolonged use or large areas may cause HPA axis suppression, Cushing's syndrome, or hyperglycemia.","Local adverse reactions include skin atrophy, striae, telangiectasias, and secondary infections.","Avoid use on face, axillae, or groin unless directed; use caution in patients with impaired skin integrity.","Not recommended for diaper dermatitis or for use under occlusive dressings."] |
| Food/Dietary | No known food interactions. Avoid excessive ingestion of corticosteroids systemically, but topical application does not require dietary restrictions. |
Loading safety data…
| Fetal Monitoring | No specific monitoring required for short-term topical use. For extended use over large areas or with occlusive dressings, monitor maternal adrenal suppression (ACTH stimulation test, cortisol levels) and fetal growth via ultrasound if used in large quantities. Assess for maternal skin atrophy or systemic effects. |
| Fertility Effects | No data available in humans. Animal studies have not shown impaired fertility with topical corticosteroids. Systemic high doses may affect fertility, but topical application with minimal absorption is unlikely to impact fertility. |
| Clinical Pearls | Amcinonide is a high-potency topical corticosteroid, typically used for short-term treatment of corticosteroid-responsive dermatoses. Due to its potency, it should be applied sparingly and not used under occlusion unless directed. Avoid use on face, groin, or axillae due to increased risk of skin atrophy and systemic absorption. Monitor for local adverse effects such as striae, hypopigmentation, or rosacea-like dermatitis. Systemic absorption can occur with extensive use, particularly in children or when applied to large body surface areas. |
| Patient Advice | Apply a thin layer to affected skin only; do not use on broken or infected skin unless prescribed. · Wash hands after application unless treating hands. · Do not cover treated area with bandages or plastic wrap unless instructed by your doctor. · Avoid contact with eyes, mouth, and mucous membranes. · Do not use for longer than prescribed; overuse can lead to skin thinning and other side effects. · Inform your doctor if you are pregnant, breastfeeding, or planning to become pregnant. |